-
First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies.
Wright D, Syngelaki A, Birdir C, Bedei I, Nicolaides KH.
Fetal Diagn Ther 2011;30:194-202. -
Body Mass Index at 11-13 Weeks' Gestation and Pregnancy Complications.
Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2011;30:250-65. -
Placental volume at 11-13 weeks' gestation in the prediction of birth weight percentile.
Plasencia W, Akolekar R, Dagklis T, Veduta A, Nicolaides KH.
Fetal Diagn Ther 2011;30:23-8. -
Ductus venosus flow at 11-13 weeks in the prediction of birth weight discordance in monochorionic twins.
Matias A, Maiz N, Montenegro N, Nicolaides K.
J Perinat Med 2011;39:467-70. -
Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11-13 Weeks?
Mastricci AL, Akolekar R, Kuppusamy R, Ahmed M, Nicolaides KH.
Fetal Diagn Ther 2011;30:53-9. -
A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester.
Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K.
Ultrasound Obstet Gynecol 2011;37:38-47. -
Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester trisomy 21 maternal serum.
Lopez MF, Kuppusamy R, Sarracino DA, Prakash A, Athanas M, Krastins B, Rezai T, Sutton JN, Peterman S, Nicolaides K.
J Proteome Res 2011;10:133-42. -
Liver volume in trisomy 21 and euploid fetuses at 11 to 13 weeks.
Gielchinsky Y, Zvanca M, Minekawa R, Persico N, Nicolaides KH.
Prenat Diagn 2011;31:28-32. -
Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study.
Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, Lun FM, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM.
BMJ 2011;342:c7401. -
First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein.
Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011;30:215-8. -
Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation.
Sebire NJ, Snijders RJM, Hughes K, Sepulveda W, Nicolaides KH.
BJOG 1996;103:999-1003. -
Down's syndrome screeening in the UK.
Nicolaides KH, Sebire NJ, Snijders RJ, Johnson S, Reynolds TM.
Lancet 1996;347:906-7. -
Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency.
Hyett JH, Sebire NJ, Snijders RJM, Nicolaides KH.
Ultrasound Obstet Gynecol 1996;7:101-3.